GTC
PTLA

Ghost Tree Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Ghost Tree Capital’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-400,000
Closed -$22.5M – 85
2017
Q2 		$22.5M Buy
+400,000
New +$16M 4.67% 3

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ghost Tree Capital's PTLA Position: Q4 2018 in Review

Ghost Tree Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2018, closing a stake of 300,000 shares — an estimated $7.99M sold.

Ghost Tree Capital first reported a position in PTLA in Q3 2014 and held it in 11 quarters. The position peaked at $11.8M in Q4 2015. 181 funds tracked by Wall St. Rank hold PTLA as of Q4 2018.

  • Ghost Tree Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Ghost Tree Capital sold 300,000 Portola Pharmaceuticals, Inc. shares in Q4 2018, an estimated $7.99M.
  • Ghost Tree Capital first reported a position in Portola Pharmaceuticals, Inc. in Q3 2014 and held it in 11 quarters.
  • Ghost Tree Capital's Portola Pharmaceuticals, Inc. position peaked at $11.8M in Q4 2015.
  • 181 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2018.

Based on Ghost Tree Capital's 13F filing for Q4 2018, filed 14 Feb 2019.